Inventiva (NASDAQ:IVA) Stock Breaks Above 50 Day Moving Average - Should You Sell?

Inventiva logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Inventiva shares rose 4.9%, briefly trading as high as $3.99 and moving above their 50-day moving average of $3.80. The stock remains below its 200-day average of $4.88.
  • Analysts remain broadly bullish, with a consensus “Buy” rating and a $15.86 average price target; Truist and Guggenheim recently raised their targets to $18 and $14, respectively.
  • Inventiva reported a quarterly loss of $0.14 per share and $0.75 million in revenue. The clinical-stage biotech is developing lanifibranor, its lead drug candidate for MASH, which is being evaluated in a Phase 3 trial.
  • Five stocks we like better than Inventiva.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report)'s share price crossed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $3.80 and traded as high as $3.99. Inventiva shares last traded at $3.83, with a volume of 3,248,993 shares.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Truist Financial raised their target price on Inventiva from $13.00 to $18.00 and gave the company a "buy" rating in a research note on Friday, October 2nd. Weiss Ratings raised shares of Inventiva from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, October 23rd. Guggenheim raised their price objective on shares of Inventiva from $11.00 to $14.00 and gave the stock a "buy" rating in a report on Tuesday, September 15th. Piper Sandler reiterated an "overweight" rating on shares of Inventiva in a research note on Wednesday, September 16th. Finally, Cantor Fitzgerald initiated coverage on Inventiva in a report on Friday, July 17th. They set an "overweight" rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Inventiva presently has a consensus rating of "Buy" and a consensus target price of $15.86.

View Our Latest Analysis on Inventiva

Inventiva Stock Up 4.9%

The company has a 50-day simple moving average of $3.80 and a two-hundred day simple moving average of $4.88.

Inventiva (NASDAQ:IVA - Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter. The company had revenue of $0.75 million for the quarter. Equities analysts anticipate that Inventiva S.A. Sponsored ADR will post -0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Seven Fleet Capital Management LP bought a new stake in shares of Inventiva during the 1st quarter worth about $1,111,000. Engineers Gate Manager LP lifted its position in Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock worth $269,000 after purchasing an additional 43,280 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Inventiva by 78.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,600 shares of the company's stock valued at $142,000 after purchasing an additional 17,000 shares in the last quarter. Platt Investment Counsel LLC acquired a new position in shares of Inventiva during the 3rd quarter valued at $45,000. Finally, Commonwealth Equity Services LLC raised its stake in shares of Inventiva by 7.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 89,853 shares of the company's stock worth $332,000 after buying an additional 5,857 shares in the last quarter. Institutional investors own 19.06% of the company's stock.

Inventiva Company Profile

(Get Free Report)

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Inventiva Right Now?

Before you consider Inventiva, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.

While Inventiva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines